Insiders PTC Therapeutics, Inc.

Equities

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
31 ^USD	+2.01%		-11.48%	+12.48%

Jul. 01	Cantor Fitzgerald Raises Price Target on PTC Therapeutics to $62 From $52, Maintains Overweight Rating	MT
Jun. 28	PTC Therapeutics Shares Drop After Negative Opinion on Muscular Dystrophy Treatment	MT

Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing	May. 24	MT
Ptc Therapeutics Insider Sold Shares Worth $273,804, According to a Recent SEC Filing	Jan. 24	MT
Replimune Group Appoints Emily Hill as CFO	23-09-19	MT
Insider Sell: Ptc Therapeutics	23-09-08	MT
PTC Therapeutics Names New CFO	23-07-17	MT
PTC Therapeutics, Inc. Appoints Pierre Gravier as Chief Financial Officer	23-07-17	CI
Insider Sell: Ptc Therapeutics	23-05-23	MT
Insider Sell: Ptc Therapeutics	23-05-12	MT
Insider Sell: Ptc Therapeutics	23-04-25	MT
Insider Sell: Ptc Therapeutics	23-04-19	MT
Insider Sell: Ptc Therapeutics	23-04-19	MT
Insider Sell: Ptc Therapeutics	23-03-29	MT
Insider Sell: Ptc Therapeutics	23-03-29	MT
Insider Sell: Ptc Therapeutics	23-03-29	MT
PTC Therapeutics Shares Fall After Chief Executive Officer Exit Announcement	23-03-24	MT
PTC Therapeutics Chief Executive Stuart Peltz Retiring, Chief Operating Officer Matthew Klein Named Successor	23-03-24	MT
PTC Therapeutics, Inc. Announces CEO Changes	23-03-24	CI
PTC Therapeutics, Inc. Appoints Matthew Klein to Board of Directors	23-03-24	CI
Insider Sell: Ptc Therapeutics	23-02-02	MT
Insider Sell: Ptc Therapeutics	23-01-12	MT

No results for this search